United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.
Current Value
$369.841 Year Return
Current Value
$369.841 Year Return
Market Cap
$16.52B
P/E Ratio
16.26
1Y Stock Return
54.26%
1Y Revenue Growth
25.04%
Dividend Yield
0.00%
Price to Book
2.7
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ATEN | 35.72% | $1.29B | +36.19% | 1.38% |
VRSK | 35.68% | $41.33B | +22.32% | 0.52% |
HALO | 35.15% | $6.18B | +21.14% | 0.00% |
MNKD | 35.09% | $1.82B | +75.73% | 0.00% |
INCY | 33.60% | $14.11B | +33.26% | 0.00% |
GRMN | 33.18% | $40.99B | +71.90% | 1.38% |
TRN | 32.78% | $3.10B | +44.00% | 2.98% |
REGN | 30.56% | $83.77B | -7.41% | 0.00% |
CTMX | 30.49% | $85.30M | -24.31% | 0.00% |
CBZ | 30.02% | $4.10B | +38.03% | 0.00% |
IONS | 28.79% | $5.70B | -29.85% | 0.00% |
HUM | 28.47% | $35.30B | -40.42% | 1.22% |
PINS | 27.81% | $20.57B | -11.80% | 0.00% |
TGTX | 27.57% | $5.46B | +143.34% | 0.00% |
TECH | 27.53% | $12.08B | +16.42% | 0.42% |
ARGX | 27.33% | $37.28B | +34.90% | 0.00% |
KBR | 27.04% | $8.14B | +14.99% | 0.96% |
PFE | 26.52% | $146.32B | -11.82% | 6.51% |
MO | 26.27% | $96.91B | +34.54% | 6.92% |
PPL | 26.19% | $25.42B | +30.65% | 2.92% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
SBUX | -25.29% | $115.09B | +4.01% | 2.29% |
LQDA | -23.22% | $950.47M | +51.35% | 0.00% |
OI | -21.59% | $1.97B | -18.81% | 0.00% |
EL | -20.59% | $27.28B | -45.32% | 3.09% |
SMG | -15.96% | $4.42B | +29.19% | 3.43% |
BVN | -15.43% | $3.06B | +28.60% | 0.00% |
SMCI | -14.96% | $24.59B | +57.69% | 0.00% |
BTCT | -14.00% | $60.65M | +335.42% | 0.00% |
ASPS | -13.02% | $22.14M | -81.89% | 0.00% |
PULM | -12.64% | $23.16M | +215.42% | 0.00% |
TCTM | -11.82% | $7.90M | -31.31% | 0.00% |
STN | -11.71% | $9.90B | +16.07% | 0.71% |
REX | -11.30% | $763.29M | -3.55% | 0.00% |
EC | -10.62% | $16.30B | -36.38% | 29.92% |
SXC | -10.62% | $1.06B | +31.73% | 3.49% |
CREG | -10.31% | $6.32M | -35.67% | 0.00% |
CLMT | -10.29% | $1.93B | +28.48% | 0.00% |
LEG | -10.19% | $1.71B | -47.42% | 8.07% |
GIB | -10.09% | $25.36B | +8.88% | 0.09% |
RDWR | -9.88% | $1.02B | +57.18% | 0.00% |
Yahoo
We think all investors should try to buy and hold high quality multi-year winners. While the best companies are hard to...
SeekingAlpha
United Therapeutics posts impressive Q3 results, driven by Tyvaso, Orenitram, and Unituxin. See why UTHR stock is a buy and poised for 40% earnings growth.
SeekingAlpha
Liquidia's collaboration on L606 boosts long-term growth potential. Find out why LQDA stockâs valuation and upcoming launches make it a strong buy.
SeekingAlpha
United Therapeutics is a leader in PAH treatments, with Tyvaso being the primary revenue driver. Check out why I rate UTHR stock a buy for long-term investors.
SeekingAlpha
United Therapeutics' pipeline and Tyvaso DPI drive strong growth. Read why UTHR stock offers substantial upside with promising treatments and cash reserves.
Yahoo
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., November 05, 2024--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Patrick Poisson, Executive Vice President, Technical Operations, will provide an overview and update on the company’s operations during a fireside chat session at the UBS Global Healthcare Conference in Rancho Palos Verdes, CA.
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
AG | -<0.01% | $1.79B | -2.46% | 0.29% |
XOS | -0.02% | $31.23M | -51.23% | 0.00% |
ARHS | -0.02% | $1.46B | +12.94% | 0.00% |
EGO | -0.03% | $3.24B | +20.90% | 0.00% |
DOCS | -0.03% | $9.97B | +117.64% | 0.00% |
WEST | -0.03% | $777.99M | -9.78% | 0.00% |
PDFS | -0.05% | $1.24B | +3.83% | 0.00% |
GTX | -0.05% | $1.81B | +9.71% | 0.00% |
COHR | 0.05% | $16.03B | +164.34% | 0.00% |
CVI | 0.05% | $1.98B | -38.88% | 7.59% |
UPLD | -0.05% | $105.10M | -22.63% | 0.00% |
CABO | 0.06% | $2.38B | -24.52% | 2.12% |
TXG | 0.06% | $1.99B | -64.42% | 0.00% |
VSTA | 0.06% | $194.41M | -41.46% | 0.00% |
CMG | 0.07% | $82.49B | +36.40% | 0.00% |
GTES | -0.08% | $5.68B | +77.53% | 0.00% |
APTV | -0.08% | $13.18B | -32.31% | 0.00% |
CNI | -0.09% | $69.87B | -6.37% | 2.20% |
ONTO | 0.09% | $8.44B | +20.33% | 0.00% |
BCC | -0.10% | $5.67B | +33.69% | 0.55% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
WEAT | -14.49% | $119.27M | 0.28% |
MSOS | -14.04% | $603.47M | 0.83% |
CNBS | -13.41% | $21.06M | 0.77% |
GSG | -13.01% | $932.06M | 0.75% |
YOLO | -12.33% | $34.63M | 1.03% |
GBIL | -12.10% | $5.68B | 0.12% |
COMT | -12.03% | $839.86M | 0.48% |
KRBN | -11.84% | $235.35M | 0.85% |
DBE | -11.65% | $50.22M | 0.77% |
VIXY | -11.39% | $195.31M | 0.85% |
PDBC | -10.69% | $4.39B | 0.59% |
DBC | -10.45% | $1.39B | 0.87% |
AMDY | -10.42% | $148.59M | 0.99% |
VRIG | -10.08% | $1.10B | 0.3% |
DBO | -9.13% | $218.47M | 0.77% |
UUP | -8.76% | $376.91M | 0.77% |
KMLM | -7.80% | $344.74M | 0.9% |
FTGC | -7.71% | $2.20B | 1.02% |
GCC | -7.59% | $136.27M | 0.55% |
IBDP | -7.18% | $2.03B | 0.1% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XONE | -0.01% | $550.19M | 0.03% |
SATO | 0.05% | $11.71M | 0.6% |
TBIL | -0.14% | $4.42B | 0.15% |
BSCO | -0.21% | $2.27B | 0.1% |
BSJO | -0.21% | $434.96M | 0.43% |
BTAL | -0.22% | $365.42M | 1.43% |
HACK | -0.26% | $1.85B | 0.6% |
DAPP | 0.36% | $204.11M | 0.51% |
SEIX | -0.42% | $268.55M | 0.62% |
QTEC | 0.45% | $3.95B | 0.57% |
HYZD | 0.51% | $161.05M | 0.43% |
BSCQ | 0.54% | $4.06B | 0.1% |
BLCN | -0.57% | $72.23M | 0.68% |
HFND | 0.57% | $35.45M | 1.22% |
EPU | 0.63% | $77.22M | 0.59% |
IXN | 0.64% | $5.21B | 0.41% |
IGPT | 0.67% | $413.69M | 0.58% |
WINN | 0.75% | $646.77M | 0.57% |
MTUM | 0.76% | $13.78B | 0.15% |
IBD | 0.81% | $332.50M | 0.44% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
PBE | 39.05% | $263.25M | 0.58% |
FBT | 38.42% | $1.19B | 0.56% |
IBB | 37.18% | $6.97B | 0.45% |
BBH | 36.23% | $421.45M | 0.35% |
FXH | 33.50% | $1.18B | 0.62% |
XBI | 32.08% | $7.29B | 0.35% |
VHT | 31.46% | $17.71B | 0.1% |
FHLC | 30.89% | $2.83B | 0.084% |
IYH | 30.22% | $3.28B | 0.39% |
USMV | 29.02% | $24.31B | 0.15% |
XLV | 28.88% | $39.43B | 0.09% |
SPLV | 28.88% | $7.80B | 0.25% |
LVHD | 26.83% | $575.42M | 0.27% |
SMMV | 26.50% | $327.89M | 0.2% |
FTCS | 26.26% | $9.20B | 0.54% |
ACWV | 26.16% | $4.35B | 0.2% |
IXJ | 26.13% | $3.98B | 0.41% |
IHE | 25.85% | $612.43M | 0.39% |
RSPH | 25.57% | $898.02M | 0.4% |
PINK | 24.88% | $164.95M | 0.5% |